Abstract Body

Studies of “elite controllers” (ECs) might lead to novel approaches for HIV cure. We characterized the clinical, immunologic and virologic characteristics of ECs with very low reservoirs (“exceptional controllers”). Such individuals may prove to be models for a functional cure.

We systematically applied a clinical case definition to identify ECs within the SCOPE cohort. A related ART-treated cohort (n=80) was used for comparison. We measured CD4 T cell-associated (CA) HIV DNA and RNA using PCR from median 9M PBMCs, HIV-specific antibody responses using luciferase immunoprecipitation systems (LIPS), and T cell responses using flow cytometry. We stratified the sample by reservoir size and compared clinical outcomes, antibody response, and T cell immunophenotypes. Exceptional controllers were defined as ECs with no detectable HIV DNA. Clinical progression was defined as loss of virus control or CD4 decline requiring ART.

96 individuals met our case definition. Median CA DNA and CA RNA was 1.5 (0-7.6) and 99 (4.8-317) copies/10^6 cells, respectively. These levels were significantly lower than those on ART (CA DNA 10.8 and CA RNA 2138 copies/10^6 cells, p<0.001 for both). CA DNA levels highly correlated with CA RNA levels (0.74, p<0.001). CA DNA levels were associated with antibody levels targeting matrix (r=0.30, p=0.008), integrase (r=0.26, p=0.03), and protease (r=0.27, p=0.02), but not envelope, or measures of T cell activation. 22 (23%) met our virologic definition of exceptional control. Exceptional controllers were more likely to have a protective HLA allele (B27 or 57; p=0.002) and less likely to progress clinically (18% vs 49%, p=0.02). Compared with the rest of the EC cohort, exceptional controllers had lower antibody levels to matrix (p=0.007), integrase (p=0.007), and protease (p=0.02), but comparable levels of T cell activation. In a logistic regression model, exceptional control was associated with presence of protective HLA alleles (6.8 fold effect, p=0.002).

We identified a subset of controllers with very low HIV DNA and RNA levels, low HIV antibody levels, and lower risk of clinical progression. These individuals are enriched for certain HLA alleles, arguing that CD8+ T responses mediate control. Such individuals may not need ART and might prove to be a model for a “functional cure” or remission.